Universe Pharmaceuticals ... (UPC)
NASDAQ: UPC
· Real-Time Price · USD
3.52
-0.04 (-1.12%)
At close: Aug 15, 2025, 2:35 PM
Universe Pharmaceuticals Balance Sheet Statement
Financials in USD. Fiscal
year is
October - September.
| Fiscal Year | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 | Q2 2021 |
| Period Ending | Mar 31, 2025 | Sep 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Mar 31, 2023 | Sep 30, 2022 | Mar 31, 2022 | Sep 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 47.27M | 29.5M | 8.86M | 5.29M | 12.95M | 5.71M | 14.24M | 8.08M | 36M |
Short-Term Investments | n/a | n/a | 2.53M | 13.22M | 13.31M | 13.15M | 14.34M | 13.73M | n/a |
Long-Term Investments | 689.02K | 712.49K | 692.49K | 685.31K | 728.05K | 702.89K | 586.67K | 744.92K | 762.5K |
Other Long-Term Assets | n/a | n/a | 96.14K | n/a | 2.33M | 2.25M | 2.52M | 2.48M | n/a |
Receivables | 13.53M | 17.88M | 14.38M | 10.73M | 17.52M | 15.18M | 19.17M | 15.81M | 17.8M |
Inventory | 4.19M | 1.74M | 3.76M | 3.34M | 2.87M | 2.21M | 3.39M | 2.46M | 4.92M |
Other Current Assets | 39.18K | 852.42K | 539.24K | 626.24K | 2.01M | 1.72M | 418.17K | 174.05K | n/a |
Total Current Assets | 65.03M | 51.64M | 33.53M | 36.81M | 52.52M | 41.51M | 51.66M | 50.48M | 61.81M |
Property-Plant & Equipment | 14.69M | 15.34M | 14.96M | 14.99M | 13.8M | 13.58M | 15.43M | 15.39M | 4.4M |
Goodwill & Intangibles | 266.78K | 262.88K | 147.65K | 148.58K | 160.47K | 157.45K | 178.76K | 178.48K | 178.57K |
Total Long-Term Assets | 15.64M | 16.32M | 15.9M | 16.48M | 17.85M | 18.03M | 19.71M | 19.66M | 5.47M |
Total Assets | 80.67M | 67.95M | 49.43M | 53.29M | 70.37M | 59.54M | 71.37M | 70.14M | 67.27M |
Account Payables | 7.4M | 4.91M | 7.76M | 4.59M | 11.24M | 3.08M | 3.65M | 5.31M | 8.59M |
Deferred Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.1M | 1.44M |
Short-Term Debt | 5.66M | 5.86M | 4.43M | 5.48M | 4.08M | 3.94M | 4.41M | 4.33M | 2.75M |
Other Current Liabilities | 10.23M | n/a | n/a | n/a | 5.44M | 3.38M | n/a | -1.1M | -1.44M |
Total Current Liabilities | 23.42M | 20.31M | 20.61M | 13.75M | 23.24M | 13.1M | 10.21M | 11.21M | 16.58M |
Long-Term Debt | 2.07M | 2.14M | 2.08M | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Liabilities | 2.07M | 2.14M | 2.08M | n/a | n/a | 7.01M | 8.06M | n/a | n/a |
Total Liabilities | 25.48M | 22.45M | 22.69M | 13.75M | 23.24M | 13.1M | 10.21M | 11.21M | 16.58M |
Total Debt | 7.73M | 7.99M | 6.51M | 5.48M | 4.08M | 3.94M | 4.41M | 4.33M | 2.75M |
Common Stock | 6.34M | 482.4K | 68.36K | 67.97K | 67.97K | 67.97K | 67.97K | 67.97K | 67.97K |
Retained Earnings | -13.46M | -10.17M | -2.94M | 10.16M | 15.61M | 16.32M | 26.79M | 25.06M | 20.89M |
Comprehensive Income | -705.84K | 1.33M | 339.12K | 26.27K | 2.17M | 772.83K | 5.02M | 4.53M | 4.13M |
Shareholders Equity | 55.18M | 45.5M | 26.74M | 39.53M | 47.13M | 46.44M | 61.16M | 58.93M | 50.69M |
Total Investments | 689.02K | 712.49K | 3.22M | 13.9M | 14.04M | 13.85M | 14.93M | 14.47M | 762.5K |